Newsroom

Sorted by: Latest

-

Growth & Investment Opportunities in the Booming Quantum AI Market: Total Revenues to Reach $7.79 Billion by 2035 at an Astonishing 35.29% CAGR - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Quantum AI Market, Till 2035: Distribution by Type of Component, Type of Deployment, Type of Application, End-User, Type of Enterprise and Geographical Regions: Industry Trends and Global Forecasts" has been added to ResearchAndMarkets.com's offering. The global quantum AI market is set to expand remarkably from USD 280 million in 2023 to USD 7.79 billion by 2035, with a CAGR of 35.29%. This market evolution underscores the synergy between quantum computing and AI,...
-

Feinstein Institutes’ Researchers Develop Promising Therapeutic for Sepsis-Induced Acute Lung Injury

MANHASSET, N.Y.--(BUSINESS WIRE)--Scientists at Northwell Health’s Feinstein Institutes for Medical Research are making strides in controlling the severe inflammation that is the hallmark of sepsis. This severe condition occurs when the body’s immune system reaction to infection causes it to attack its own tissues and organs, often resulting in organ failure or death. Researchers have uncovered a critical mechanism driving acute lung injury (ALI) in sepsis, identifying a novel subset of neutrop...
-

Robbins LLP Reminds Freeport-McMoran Inc. Stockholders of the January 12, 2026 Lead Plaintiff Deadline – Contact us today for information about the FCX class action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Freeport-McMoran Inc. (NYSE: FCX) is a mining company. What is the class period? February 15, 2022 - September 24, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Freeport during the class period because the Company allegedly misled investors regarding safety at its mines. For more information, submit a form, email attorney Aaron Dumas, Jr....
-

VHP Foundation Completes Its First Year of Operations, Including Inaugural Funding of Three Charities

LOS ANGELES--(BUSINESS WIRE)--The VHP Foundation (“VHPF” or the “Foundation”), the internal philanthropic arm of Varsity Healthcare Partners, a leading lower middle market healthcare services private equity firm, announced today that it has completed its first year of operations, making funding commitments to three charitable organizations that meet VHPF’s 2025 funding priorities and broader mission: One More Wave, The Ferrari Kid, and Because I Said I Would. Established in 2024, The VHP Founda...
-

AI Transformation in China's E-Commerce Ecosystem: Regulation, Infrastructure, and Digital Payments Integration 2025-2030 - Heavy Investment and Digital Infrastructure Fuel China's Global Leadership - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "AI Transformation in China's E-Commerce Ecosystem: Regulation, Infrastructure, and Digital Payments Integration 2025" has been added to ResearchAndMarkets.com's offering. This report delivers comprehensive insights into how Artificial Intelligence (AI), particularly Generative AI, is transforming China's E-Commerce, fintech, and payments landscape through large-scale platform integration, regulatory innovation, and digital infrastructure expansion. China expands en...
-

New Coalition Launched to Protect U.S. Quartz Industry and Jobs

WASHINGTON--(BUSINESS WIRE)--Today, more than 1,000 U.S. fabricators, installers, distributors, and suppliers joined together to launch Save Quartz Jobs, a national Coalition dedicated to protecting American jobs and ensuring continued access to affordable quartz surfaces — one of the most widely used materials in home construction and renovation. The Coalition was created in response to a Section 201 “safeguard” investigation by the U.S. International Trade Commission (ITC) resulting from a pe...
-

ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer...
-

Angeleno Group and Energy Impact Partners Announce AUD$50M Commitment to IND Technology – The Leading Global Provider of Early Fault Detection (EFD™) Systems to Prevent Grid Failures and Reduce the Risk of Wildfires

MELBOURNE, Australia & LOS ANGELES & NEW YORK--(BUSINESS WIRE)--Angeleno Group, the pioneering Los Angeles-based investment firm providing venture capital and growth equity to clean energy and climate solutions companies, and Energy Impact Partners LP (EIP), a global technology investor specialized in the energy transition, announced today a AUD $50 million commitment to IND Technology, the leading global provider of Early Fault Detection (EFD™) systems to prevent power outages and wildfires ca...
-

MediaCo Holding Inc.’s EstrellaTV Delivers Record-Setting Prime-Time Performance with Liga MX Finals Coverage

NEW YORK--(BUSINESS WIRE)--MediaCo Holding Inc. (Nasdaq: MDIA), today announced a standout prime-time performance for EstrellaTV, driven by coverage of the first leg of the Liga MX Finals between Tigres and Toluca. The highly anticipated matchup delivered EstrellaTV’s largest P2+ prime-time audience of 2025, averaging 185.4 thousand viewers, as Tigres claimed a 1–0 win in the opening match of the championship series. Among both P18-49 and P25-54, EstrellaTV posted its second-highest Thursday pr...
-

Cure Rare Disease Awarded $7.4 Million CIRM Grant to Advance Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2i/R9

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD) announced it has been awarded a $7.4 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of a novel gene therapy for Limb-Girdle Muscular Dystrophy Type 2i/R9 (LGMD2i/R9), a progressive neuromuscular disorder with limited treatment options. Cure Rare Disease launched its LGMD2i/R9 program to develop a therapeutic solution for patients suffering from this rare condition. The program, C...